CN108265079A - 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 - Google Patents
一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 Download PDFInfo
- Publication number
- CN108265079A CN108265079A CN201710000306.0A CN201710000306A CN108265079A CN 108265079 A CN108265079 A CN 108265079A CN 201710000306 A CN201710000306 A CN 201710000306A CN 108265079 A CN108265079 A CN 108265079A
- Authority
- CN
- China
- Prior art keywords
- rsv
- cx3c
- fusion protein
- pref
- syncytial virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 86
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 86
- 241000700605 Viruses Species 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 210000002345 respiratory system Anatomy 0.000 title claims abstract description 14
- 239000000969 carrier Substances 0.000 title claims abstract description 13
- 108091006027 G proteins Proteins 0.000 claims abstract description 19
- 102000030782 GTP binding Human genes 0.000 claims abstract description 19
- 108091000058 GTP-Binding Proteins 0.000 claims abstract description 19
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 19
- 229960005486 vaccine Drugs 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000018417 cysteine Nutrition 0.000 claims abstract description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 11
- 239000013613 expression plasmid Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- 238000005457 optimization Methods 0.000 claims description 4
- 101710135378 pH 6 antigen Proteins 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000004114 suspension culture Methods 0.000 claims description 2
- 108700010070 Codon Usage Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- 210000001728 clone cell Anatomy 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 5
- 238000012827 research and development Methods 0.000 abstract description 4
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 238000007877 drug screening Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 12
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 4
- 102000013818 Fractalkine Human genes 0.000 description 4
- 239000005482 chemotactic factor Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000003257 protein preparation method Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001282153 Scopelogadus mizolepis Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18533—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/102—Plasmid DNA for yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/103—Plasmid DNA for invertebrates
- C12N2800/105—Plasmid DNA for invertebrates for insects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物技术领域,具体公开了一种新型呼吸道合胞体病毒pre‑F融合蛋白载体的制备方法和应用。所述的RSV pre‑F融合蛋白载体由如下方法制备得到:将第三个半胱氨酸(第182位)突变为丝氨酸的G蛋白CX3C类似域的天然颈环loop结构域连接到pre‑F的铰链区。所述的RSV pre‑F融合蛋白保持了RSV pre‑F的
Description
技术领域
本项发明属于生物技术领域,该发明涉及一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法和应用。
背景技术
呼吸道合胞病毒(Respiratory syncytial virus,RSV)属于副黏病毒科,肺炎病毒属,病毒粒子直径为150~300nm,为负链RNA病毒。在RSV外膜具有G、F、SH等跨膜糖蛋白,其中RSV F和RSV G两种糖蛋白,是激发机体产生保护性抗体的最主要的病毒抗原,是呼吸道合胞病毒疫苗研究开发的重要内容。目前临床上使用的RSV治疗性帕丽珠抗体的目标蛋白也是RSV F蛋白。
RSV F蛋白同流感的HA和HIV-1的env蛋白一样,都是I型融合糖蛋白。病毒在细胞内首先表达前体蛋白F0(pre-F),然后进行酶切后形成三个聚合的多肽p27、F2和F1,经过结构重排F2和F1形成一个稳定的成熟结构(post-F)才能被激活病毒与细胞膜融合功能。为了形成有功能的post-F构象,pre-F蛋白通过打开回折区域1(refolding region 1,RR1)、融合功能区和heptad repeat A(HRA)形成长的螺旋结构,此时位于RR1末端的融合多肽就能介导病毒和细胞膜的融合。目前在F蛋白上已经发现至少有五种中和位点,位点I,II和IV是pre-F和post-F构型上共有的位点。其中位点II是RSV治疗性抗体帕丽珠抗体治疗靶点。但pre-F比post-F具有更多的中和表位。如近两年在pre-F蛋白的顶端发现的一个特有的中和位点,被称为位点,该位点诱导产生的中和抗体有D25、AM22和5C4,它们的中和活性是帕丽珠的10-100倍,另外一个pre-F蛋白特异的中和位点能够被单抗MPE8识别,这个位点虽然被定为到中和位点II附近, 但是只存在pre-F构型中。还有一个pre-F特异性抗体AM14,只识pre-F蛋白的三聚体结构。
研究表明利用pre-F蛋白吸附人血清后,血清的中和活性减少了90%,这表明了人血清中主要的中和抗体是针对preF的特异性抗体。小鼠研究表明利用pre-F蛋白免疫后,诱导的中和抗体滴度是post-F蛋白诱导滴度的4-10倍;其低剂量的免疫的情况下,也能够起到很好的保护作用。另外利用pre-F蛋白免疫后,其免疫致病现象也低于post-F蛋白。因此,目前RSV pre-F蛋白亚单位疫苗是RSV疫苗开发的主要关注点。
RSV G蛋白是一个被膜蛋白,是RSV激发机体产生保护性抗体最重要的病毒蛋白之一,其可以诱导机体产生显著的血清中和抗体和粘膜免疫力,能有效防止RSV再感染。RSV G外膜蛋白130~230位氨基酸为保守氨基酸,在173位、176位、182位及186位有四个半胱氨酸两两形成二硫键,形成了一个颈环loop结构,其结构类似趋化因子fractalkine的CX3C结构域。在病毒感染过程中,G蛋白的CX3C相似域通过竞争性地结合免疫细胞上的fractalkine受体CX3CR1,干扰机体产生相应的细胞因子和趋化因子等正常免疫反应,起到免疫逃避的作用。因此利用CX3C保守区域制备的疫苗能够阻止G蛋白的CX3C-CX3CR1相互作用,从而避免RSV感染后操纵机体免疫和发炎反应,减少免疫致病现象,该方法是一个有效开发RSV疫苗的一个策略。
本研究通过G蛋白CX3C区域天然的颈环loop结构域连接到pre-F的铰链区,构建RSV preF-CX3C融合蛋白,有效防止pre-F发生回折而锁定pre-F的a4-a5区域,利用昆虫细胞-杆状病毒表达系统进行表达该融合蛋白,并进行纯化后,能够获得高免疫原性的RSVpreF-CX3C融合蛋白。该融合蛋白既保持了RSV pre-F的位点的构象,保证了其高免疫原性和pre-F的中和位点,能够诱导高水平、高中和能力的pre-F和post-F的中和抗体。同时利用G蛋白的CX3C相 似域免疫原性,能够诱导中和CX3C的结构抗体,阻止RSV感染后G蛋白同CX3C的结构结合CX3CR1的能力,从而减少RSV病毒对机体免疫的操控,从而减轻免疫造成的损伤。同时将G蛋白的CX3C相似域第三个半胱氨酸(第182位)突变为丝氨酸,从而避免其与趋化因子CX3C结构相似性,减少产生对体内fractalkine的CX3C结构中和作用抗体,从而降低对体内fractalkine功能的损坏。因此本研究构建的RSV preF-CX3融合蛋白,不仅能够诱导高水平的中和抗体,同时具有抑制RSV免疫调控功能,具有较好的应用价值。
因此,本发明所描述的RSV preF-CX3C融合蛋白载体可应用于以下方面:1)抗RSV的疫苗的开发;2)抗其他传染病的疫苗载体;3)抗RSV中和抗体及药物的筛选工具等。
发明内容
本发明所要解决的技术问题是,为了克服现有技术的上述问题,提供一种新型呼吸道合胞体病毒pre-F融合蛋白RSV preF-CX3C融合蛋白载体。
本发明的另一个目的在于提供一种新型呼吸道合胞体病毒pre-F融合蛋白RSVpreF-CX3C的制备方法。
本发明所采取的技术方案是:
一种表达RSV preF-CX3C融合蛋白的载体,该载体含有以下结构表达框:通过将第三个半胱氨酸(第182位)突变为丝氨酸的G蛋白CX3C区域天然的颈环loop结构域,RSV的胞外区,其中突变为丝氨酸的G蛋白CX3C区域天然的颈环loop结构域连接到pre-F a4-a5区域的铰链区。
进一步的,上述表达RSV preF-CX3C融合蛋白的载体保护以下表达框:RSV preF-CX3C融合蛋白位于寄主偏爱启动子下游,构成“启 动子-RSV preF-CX3C”的结构。
一种表达RSV preF-CX3C融合蛋白载体的方法,包括如下步骤:
S1.经过寄主编码子优化后,基因全合成得到RSV preF-CX3C融合蛋白。
S2.把RSV preF-CX3C融合蛋白的全长序列插入骨架载体的启动子下游,得到RSVpreF-CX3C融合蛋白表达质粒载体。
进一步将RSV preF-CX3C融合蛋白表达质粒转染至哺乳细胞、昆虫细胞或酿酒细胞中。
进一步的,上述骨架载体根据宿主细胞类型选择相应的骨架载体。优选的,上述表达RSV preF-CX3C融合蛋白载体的宿主细胞为293、酵母细胞和Spodoptera frugiperda草地夜蛾细胞Sf9。
进一步的,上述优化RSV preF-CX3C融合蛋白基因序列如SEQ ID NO.1所示;
S3.新型呼吸道合胞体病毒pre-F融合蛋白其制备方法包括以下步骤:
1)将上述的RSV preF-CX3C融合蛋白的载体转染到相应的宿主细胞后,经过筛选后培养后可获得表达RSV preF-CX3C融合蛋白的细胞系;
2)将步骤1)筛选获得RSV preF-CX3C融合蛋白稳定的表达细胞系经过大规模培养即可获得RSV preF-CX3C融合蛋白。
进一步的,上述新型呼吸道合胞体病毒pre-F融合蛋白其制备方法,包括以下步骤:
1)将表达RSV preF-CX3C融合蛋白的载体转染293细胞系,用不同浓度的G418培养基培养,筛选有抗性的细胞克隆株,即得到表达RSV preF-CX3C融合蛋白的细胞系。
2)将上一步获得的表达RSV preF-CX3C融合蛋白的细胞系进行悬浮培养,获得RSVpreF-CX3C融合蛋白,即为新型呼吸道合胞体病毒pre-F融合蛋白。
将上述步骤2)中得到的RSV F-G CX3C融合蛋白上清经过经过镍琼脂糖凝胶和阴离子交换柱,收集纯度较高区段的纯化样品,为RSV F-CX3C融合蛋白,即为新型呼吸道合胞体病毒pre-F融合蛋白,可以为免疫样品。
所述的呼吸道合胞体病毒pre-F融合蛋白载体在制备抗人RSV病毒的疫苗的应用。
所述的呼吸道合胞体病毒pre-F融合蛋白载体在制备抗人RSV病毒的药物的应用。
所述的呼吸道合胞体病毒pre-F融合蛋白载体在制备疫苗的应用。
所述的呼吸道合胞体病毒pre-F融合蛋白载体在制备中和抗体的应用。
本发明有益效果:(1)本发明所述的载体能够在293、昆虫细胞等辅助细胞株中大量分泌生产新型呼吸道合胞体病毒pre-F融合蛋白,并可以浓缩纯化;(2)该重组载体保持了RSV pre-F的位点的构象,能够诱导高水平、高中和能力的pre-F和post-F的中和抗体,减少RSV病毒对机体免疫的操控,减轻免疫造成的损伤;(3)本发明所述重组载体可作为疫苗或基因治疗载体,还可应用于药物及中和抗体的研发,以及报告示踪系统等。
附图说明
附图1是RSV preF-CX3C融合蛋白表达质粒构建程示意图。
附图2是RSV preF-CX3C融合蛋白表达质粒酶切鉴定结果。
附图3是RSV preF-CX3C融合蛋白表达质粒转染细胞表达Western blot鉴定结果。
附图4是Ni柱纯化RSV preF-CX3C融合蛋白的纯化结果。
附图5是通过夹心ELISA方法鉴定RSV preF-CX3C融合蛋白抗体结合能力,分析确定蛋白结构。A:包被His抗体,B:包被preF抗体,C:包被G蛋白CX3C保守区抗体,检测抗体为帕丽珠抗体。
附图6是检测免疫小鼠血清特异性IgG抗体滴度,RSV preF-CX3C融合蛋白的免疫原性结果。
附图7是检测免疫小鼠血清中和抗体滴度,RSV preF-CX3C融合蛋白诱导特中和抗体滴度结果。
具体实施方法
下面结合具体实验,进一步说明本发明的技术方案。
1主要材料
病毒:RSV-A2株;
细胞:293细胞系、Hep-2。
2主要试剂
病毒RNA抽提试剂盒(上海生工);cDNA反转录试剂盒(Fermentas,Thermo);PremerStar DNA聚合酶(大连宝生物);各种DNA消化酶, BamHI、HindIII,T4连接酶购自Fermentas。LB培养基;
转染试剂:PEI(Sigma);RSV F
蛋白抗体:pre-F抗体,G蛋白CX3C抗体(本公司制备);His tag抗体,帕丽珠抗体,HRP羊抗人二抗。
实施案例1、RSV preF-CX3C融合蛋白基因合成
从Genebank里面调取的RSV F蛋白基因序列,利用软件进行分析比对,进行全序列合成得到F蛋白基因,设计特异性引物扩增F蛋白全长基因。通过软件分析RSV F蛋白的结构,然后加入G蛋白的核心区域CX3C,尾部加入his标签,方便进行纯化。通过基因优化后,进行基因合成全部序列,并在启动子前加入kozak序列。为了把序列插入相应的载体,序列前后加入HindIII和BamHI酶切位点。
实施案例2、RSV preF-CX3C融合蛋白表达质粒的构建
以pcDNA3.1为载体,把融合蛋白的全长序列插入载体,构建下图穿梭质粒(图1)。并通过酶切验证和测序,证明插入序列正确(图2),得到RSV preF-CX3C融合蛋白表达质粒pcDNA3.1-L3131G。
实施案例3表达质粒转染293细胞
转染前24h内,传代293T细胞至含10%胎牛血清的DMEM培养基中,接种到六孔板中。转染前1h,将细胞培养基更换为Opti-MEM。用100ul体积的Opti-MEM稀释1μg的RSVpreF-CX3C融合蛋白表达质粒pcDNA3.1-L3131G,小心混匀,记为A液;用相等体积的Opti-MEM稀释3ug的PEI(1ug/ul),小心混匀,记为B液(质粒:PEI=1:3,W/W),室温静止5min。将B液缓慢加到A液中并混匀,最好使用旋涡振荡器边加边震荡。然后室温放置20min。将DNA-PEI混合液缓慢加入到细胞培养基中,轻轻混匀。第三天收集上清和细胞检查蛋白表达情况。WB结果表明用帕丽珠抗体能够在转染质粒 pcDNA3.1-L3131G的细胞中能够检测到大约55Kd的条带,与预期的大小相符合(图3)。
实施案例4.RSV preF-CX3C融合蛋白稳定细胞系筛选、悬浮培养、表达和纯化
(1)RSV preF-CX3C融合蛋白稳定细胞系筛选
将冻存的293细胞复传代3至4次使细胞达到良好的生长状态,提前一天铺24孔板(20000/孔)。第二天进行以上方法分别转染pcDNA3.1-L3131G和pcDNA3.1-post-F,4小时后换新鲜正常培养基。转染24小时后加含有1200ug/ml的G418培养基,两天后换液一两次。培养6天左右细胞大量死亡时,可以换用含有300ug/ml的G418适应性培养基,维持筛选压力。筛选约14天后可见有抗性克隆出现,在高倍镜下标记阳性克隆,套环法或刮除法结合有限稀释法筛选阳性克隆,将其转入多孔板培养。扩大培养后,进行冻存。
(2)RSV preF-CX3C融合蛋白稳定细胞系悬浮培养
取出转染的293细胞,先在T75形组织培养瓶中传代扩增到4瓶,用胰蛋白酶消化液消化,转移到CO2摇床培养箱的摇瓶中,加入30ml悬浮培养基293SFM(Hyclone)进行适应性培养,转速为110rmp。经过两天的适应性传代扩增后,培养的第3天摇床速度提高到120rpm,第4天逐步提高摇床速度进行培养,使细胞培养密度达到4-6×106cells/ml后,离心后分别收集上清和少量细胞,western检测这两部分目的基因。余下细胞用新鲜的悬浮培养基稀释到1×106cells/ml后进行传代扩大培养,收集2L上清溶液保存到4度冰箱,以备蛋白纯化。
(3)RSV preF-CX3C融合蛋白表达上清的澄清和浓缩
将转染转染pCDNA3.1-L3131G和pCDNA3.1-post-F质粒的稳定细胞系,进行扩大培养,并收集上清。然后将表达上清也装入250ml的离 心杯中,配平。使用JA-14转子(BECKMAN),20000g,10min,4℃。将上清取出,澄清的液体保存在4度。将上述澄清也用膜包(pellicon膜包,30KD、50cm2,用PBS冲洗30min,保证包膜出口的液体的pH为中性)进行浓缩,蠕动泵的转速为80ml/min。溶液浓缩10倍后,停止浓缩。浓缩液保存在4℃。
(4)RSV preF-CX3C融合蛋白Ni柱纯化
取纯化Ni柱,清洗干净柱子,加入3-4ml镍琼脂糖凝胶,用洗瓶清洗柱子5次,再用平衡液平衡柱子2次。将镍琼脂糖凝胶填料和上清混合,放置四维旋转混匀器上孵育1-2h充分结合后,离心浓缩填料,装柱。用20倍柱体积平衡缓冲液洗脱未吸附的样品,流速1-2ml/min,然后用50mM,100mM,300mM咪唑浓度分阶段洗脱柱子,流速1-2ml/min洗脱5-10个柱体积左右,2ml/管收集。将收集的各浓度梯度洗脱下来的蛋白,取样进行SDS-Page纯度鉴定,合并收集纯度较高的区段,经过以上步骤DNA、杂蛋白去除率可以达到90%以上,纯化的样品即为RSV F-CX3C抗原(图4)。
实施案例5.夹心ELISA方法蛋白结构鉴定
用包被缓冲液分别将pre-F抗体12B4、HIS抗体和G蛋白CX3C抗体稀释至蛋白质含量为1μg/mL,在酶标板反应孔中加0.1mL,4℃过夜。次日弃去孔内溶液,用洗涤缓冲液每次3min洗板3次。加一定浓度稀释的待检样品(同时做空白对照,阴性对照孔及阳性对照)0.1mL于上述已包被的反应孔中,37℃孵育1hr。用洗涤缓冲液每次3min洗板3次后,加入1:1000稀释的帕丽珠抗体0.1ml。37℃孵育1hr,用洗涤缓冲液洗板3次,每次3min。加入羊抗人酶标抗体0.1ml。37℃孵育1hr,用洗涤缓冲液洗板3次,每次3min。然后TMB加底物液37℃显色10-30min。最后各反应孔中加入终止液0.05mL终止反应。将酶标板在酶标仪上,于450nm进行结果判定读 数。结果表明该融合蛋白能够被帕丽珠抗体、pre-F抗体、G蛋白CX3C保守区抗体识别,说明该融合蛋白保持了pre-F蛋白的构象,并保存了G蛋白CX3C保守区免疫原性(图5)。
实施案例6、RSV F-CX3C融合疫苗效力分析
(1)RSV preF-CX3C融合疫苗的制备
分别将RSV preF-CX3C融合蛋白和post-F蛋白制备溶于PBS缓冲液中,浓度为10ug/ml,然后加入1/10体积的AL(OH)3佐剂(1000mg/ml)混合,分装成100ul每支得到疫苗。
(2)疫苗纯度检测
根据《中国药典(第3版)》及《中国生物制品规程》,检测疫苗成品的外观,无菌DNA含量、蛋白含量检测,以及PH值等。本实验共试制了两批疫苗,检测结果如表1。两次结果表明两次结果没有明显差异,说明该疫苗制备方法稳定、可靠。
附表1是根据《中国药典(第3版)》及《中国生物制品规程》对制备的两批次的RSVF-CX3C融合疫苗纯度的检测结果。
项目 | 第一批 | 第二批 |
外观 | 透明液体 | 透明液体 |
蛋白含量 | <120ug/剂量 | <120ug/剂量 |
DNA含量 | <10ug/剂量 | <10ug/剂量 |
内毒素 | <100EU/剂量 | <100EU/剂量 |
抗原含量 | 7-12ug/剂量 | 8-11ug/剂量 |
无菌检查 | 阴性 | 阴性 |
PH | 6.8-7.3 | 6.8-7.2 |
效力 | 通过 | 通过 |
(3)RSV preF-CX3C抗原疫苗小鼠免疫
为了验证该表达产生的RSV preF-CX3C融合疫苗的免疫原性,本实验通过大量表达RSV preF-CX3C融合蛋白,并经过以上纯化步骤后制备出疫苗,利用以上10ug纯化的VLP对六周龄的BALB/c母鼠分别在0,2,4周进行免疫三次,每次每只免疫10ug。同时设置EV71灭活病毒阳性对照和PBS阴性对照,六周后进行采血。
(4)免疫小鼠血清抗体滴度
利用浓度为0.5ug/ml纯化的RSV preF-CX3C融合蛋白包被板条,包被过夜,每孔100ul。然后用10%FBS进行封闭后,梯度稀释各个血清样品,加入100ul到包被的RSV preF-CX3C融合蛋白板中,37度孵育2小时后,洗涤5次后,加入特异性小鼠IgG检测抗体,37度孵育1小时后,加入反应底物显色10min后,加入终止液,读取OD值。其OD值大于本底值0.2以上的为阳性值。参阅图6,结果表明以上RSV F-CX3C融合蛋白能够诱导106以上的RSV preF-CX3C融合蛋白特异性IgG抗体,而PBS对照组没有检测到RSV preF-CX3C融合蛋白特异性IgG抗体,明显高于post-F蛋白疫苗的免疫原性(图6)。
(5)免疫小鼠血清中和抗体滴度
提前一天准备Hep-2细胞,待细胞铺满后。取各组小鼠血清样品,放到56度水浴锅中灭活30min。用2%的FBS培养基从倍比稀释。将RSV病毒用2%的FBS培养基稀释到100TCID50/100微升。稀释后的病毒液、样品各取300微升,混合均匀,在37度细胞培养箱放置2小时。吸去Hep-2细胞培养上清,取100微升混合液加入到6个孔Hep-2细胞中,放入37度继续培养。逐日观察细胞病变,当无血清病毒感染组出现++++病变时,停止观察,记录各个细胞孔的病变情况,并进行计算获得中和效价。结果RSV preF-CX3C融合蛋白能够诱导210以上的RSV中和效价,post-F蛋白只能诱导26中和效价(图7)。
以上所述实施例仅表达了本项发明的几种实施方式,这些实施例的描述清晰、具体,这些实施例的表述不可理解为对本项发明专利的限制。需要强调的是,对于本研究领域的科研技术人员,在根据本项发明构思的前提下,还能够做出若干变化和改进,这些属于本项发明的保护范围。因此,本项专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法,其特征在于,由如下方法制备得到:基因全合成法将G蛋白CX3C类似域天然的颈环loop结构域直接连接到pre-F蛋白的a4-a5区域铰链区。
2.根据权利要求1所述的呼吸道合胞体病毒pre-F融合蛋白载体,其特征在于:G蛋白CX3C类似域的第三个半胱氨酸(第182位)突变为丝氨酸。
3.权利要求1或2所述的呼吸道合胞体病毒pre-F融合蛋白载体的制备方法,其特征在于,包含如下步骤:S1.基因全合成得到RSV G蛋白核心区CX3C第182位为丝氨酸的RSVpreF-CX3C融合蛋白基因序列。S2.根据RSV preF-CX3C融合蛋白的全长基因序列插入骨架载体,得到表达RSV preF-CX3C融合蛋白表达质粒。
4.根据权利要求1所述的呼吸道合胞体病毒pre-F融合蛋白载体,其特征在于:应用哺乳细胞、昆虫细胞-杆状病毒和酵母等表达系统进行表达。
5.根据权利要求3所述的所述的呼吸道合胞体病毒pre-F融合蛋白载体制备方法,其特征在于:所属骨架载体根据寄主细胞类型选择相应的骨架载体。
6.根据权利要求3、5所述的所述的呼吸道合胞体病毒pre-F融合蛋白载体制备方法,其特征在于:所属骨架载体为pFastBac、pcDNA3.1、pVIV02或pBudCE4.1载体等。
7.根据权利要求1所述的制备方法,其特征在于,所述步骤S1为:根据RSV preF-CX3C基因全序列进行寄主密码子偏爱性优化后,合成得到RSV preF-CX3C融合蛋白。
8.根据权利要求1所述的所述的呼吸道合胞体病毒pre-F融合蛋白载体制备方法,其特征在于,所述步骤步骤以下s1将权利要求1-3任一所述的或权利要求4-8所述任一制备方法制备的RSV preF-CX3C融合蛋白表达质粒,转染到293T细胞培养基中,筛选阳性克隆细胞。S2将上一步获得的RSV preF-CX3C融合蛋白293T表达细胞进行悬浮培养后,初步离心去除细胞碎片后,收集上清浓缩后,经过未纯化得到RSV preF-CX3C融合蛋白。S3将上述步骤2)中得到的RSV preF-CX3C融合蛋白上清经过经过镍琼脂糖凝胶和阴离子交换柱,收集纯度较高区段的纯化样品为RSV preF-CX3C抗原,即为新型呼吸道合胞体病毒pre-F融合蛋白,可以为免疫样品。
9.权利要求1或2所述的新型呼吸道合胞体病毒pre-F融合蛋白在制备抗人RSV病毒的疫苗或抗人RSV病毒药物中的应用。
10.权利要求1或2所述的新型呼吸道合胞体病毒pre-F融合蛋白在制备疫苗、中和抗体或生物学报告示踪系统中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710000306.0A CN108265079A (zh) | 2017-01-02 | 2017-01-02 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710000306.0A CN108265079A (zh) | 2017-01-02 | 2017-01-02 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108265079A true CN108265079A (zh) | 2018-07-10 |
Family
ID=62771496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710000306.0A Pending CN108265079A (zh) | 2017-01-02 | 2017-01-02 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108265079A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115772230A (zh) * | 2022-07-18 | 2023-03-10 | 青岛硕景生物科技有限公司 | 一种rsv重组抗原、其制备方法及应用 |
CN116836243A (zh) * | 2022-09-23 | 2023-10-03 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264323A (zh) * | 2007-12-19 | 2008-09-17 | 昆明理工大学 | 呼吸道合胞病毒亚单位疫苗、制备方法和应用 |
CN102131830A (zh) * | 2008-07-18 | 2011-07-20 | 魁北克益得生物医学公司 | 嵌合呼吸道合胞病毒多肽抗原 |
CN103842374A (zh) * | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | 融合前的rsv f抗原 |
WO2014160463A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
WO2014174018A1 (en) * | 2013-04-25 | 2014-10-30 | Crucell Holland B.V. | Stabilized soluble prefusion rsv f polypeptides |
EP2975052A1 (en) * | 2013-03-15 | 2016-01-20 | Xiamen University | Epitope of rsv fusion protein and antibody identifying same |
-
2017
- 2017-01-02 CN CN201710000306.0A patent/CN108265079A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264323A (zh) * | 2007-12-19 | 2008-09-17 | 昆明理工大学 | 呼吸道合胞病毒亚单位疫苗、制备方法和应用 |
CN102131830A (zh) * | 2008-07-18 | 2011-07-20 | 魁北克益得生物医学公司 | 嵌合呼吸道合胞病毒多肽抗原 |
CN103842374A (zh) * | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | 融合前的rsv f抗原 |
WO2014160463A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
EP2975052A1 (en) * | 2013-03-15 | 2016-01-20 | Xiamen University | Epitope of rsv fusion protein and antibody identifying same |
CN105722856A (zh) * | 2013-03-15 | 2016-06-29 | 厦门大学 | Rsv融合蛋白的表位以及识别其的抗体 |
WO2014174018A1 (en) * | 2013-04-25 | 2014-10-30 | Crucell Holland B.V. | Stabilized soluble prefusion rsv f polypeptides |
Non-Patent Citations (4)
Title |
---|
ANDERS KRARUP ET AL.: "A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism", 《NATURE COMMUNICATIONS》 * |
JASON S. MCLELLAN ET AL.: "Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody", 《SCIENCE》 * |
PATRICIA A. JORQUERA ET AL.: "Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease", 《PLOS ONE》 * |
王应明等: "呼吸道合胞病毒G和F蛋白诱导细胞因子免疫反应的研究进展", 《免疫学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115772230A (zh) * | 2022-07-18 | 2023-03-10 | 青岛硕景生物科技有限公司 | 一种rsv重组抗原、其制备方法及应用 |
CN116836243A (zh) * | 2022-09-23 | 2023-10-03 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112321688B (zh) | 稳定的冠状病毒重组蛋白二聚体及其表达载体 | |
CN106929482A (zh) | 定点突变的流感病毒、其活疫苗及其制备方法和应用 | |
CN112175914A (zh) | 蛋白水解靶向病毒、其活疫苗及其制备方法和用途 | |
CN102614507B (zh) | 一种o型口蹄疫分子标记疫苗及其制备方法 | |
CN103384531A (zh) | 经修饰流感血凝素蛋白及其用途 | |
CN113943375B (zh) | 一类来源于新型冠状病毒s2蛋白hr区域的重组融合蛋白及其应用 | |
CN107674883A (zh) | 重组猪瘟e2蛋白及其亚单位疫苗的制备方法和应用 | |
CN106381288B (zh) | 一种抗h3n2亚型犬流感病毒核蛋白单克隆抗体杂交瘤2d10及单克隆抗体 | |
CN104059927B (zh) | 鸡新城疫糖蛋白病毒抗原的制备方法及其产品 | |
CN116350769A (zh) | 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用 | |
CN102397559B (zh) | 广谱型流感疫苗及其制备方法 | |
CN101879312B (zh) | 广谱型流感疫苗及其制备方法 | |
CN108265079A (zh) | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 | |
CN108348596A (zh) | 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 | |
CN101322844B (zh) | 无病毒非结构蛋白的口蹄疫疫苗及其制备方法 | |
CN109136199A (zh) | 一种表达h5亚型ha的复制缺陷型重组h9n2禽流感病毒 | |
CN104829732A (zh) | 一种重组蛋白及其在昆虫杆状病毒表达系统中的表达方法 | |
CN106119287B (zh) | 一种表达呼吸道合胞病毒f蛋白的重组载体及方法 | |
US20160228536A1 (en) | Recombinant respiratory syncytial virus (rsv) and vaccines | |
CN116063572A (zh) | 一种同时表达bvdv e2蛋白和brsv f蛋白的融合蛋白及二联亚单位疫苗 | |
CN101220095A (zh) | 抗呼吸道合胞病毒f蛋白和g蛋白的免疫球蛋白制备方法 | |
CN113896773A (zh) | 重组fcv抗原及猫嵌杯病毒基因工程亚单位疫苗 | |
KR20180115717A (ko) | 이종 에피토프 및/또는 성숙 절단 부위를 갖는 인플루엔자 헤마글루티닌 조성물 | |
CN106754722A (zh) | 稳定表达牛胰蛋白酶原的Vero细胞系及其用途 | |
CN110042084A (zh) | 一种活病毒流感疫苗的生产方法以及制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180710 |